270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy